Amryt Pharma PLC - pharmaceutical company - Reports results from Phase 3 EASE trial of Filsuvez medication for epidermolysis bullosa skin condition. Says primary endpoint met with "statistical significance". Says 41% of patients taking medication saw complete closure of EB wounds within 45 days, compared to 29% in control group. EB is a skin condition which causes skin fragility.
Current stock price: 209.00 pence
Year-to-date change: up 71%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
